Glow Stack (GHK-Cu + BPC-157 + Epithalon) (50mg + 5mg + 10mg)
Research skin regeneration & tissue repair stack combining three mechanisms: GHK-Cu for collagen synthesis & antioxidant protection, BPC-157 for angiogenesis & healing, Epithalon for telomerase activation. Trending 2026 stack (Skin Rejuvenation Stack) in the regenerative peptide research literature.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
**GHK-Cu** activates 4,000+ genes related to collagen, elastin synthesis, and antioxidant enzymes (SOD, glutathione). **BPC-157** promotes angiogenesis via VEGFR2/FAK signaling, enhancing tissue perfusion. **Epithalon** activates telomerase (hTERT), elongating telomeres in somatic cells. The combination targets: extracellular matrix (GHK-Cu) + vascular repair (BPC-157) + cellular aging (Epithalon).
Quick Start
- GHK-Cu: 1–2 mg SC, 1×/day (morning)
- BPC-157: 250–500 mcg SC, 1–2×/day
- Epithalon: 5 mg SC, 1×/day (evening) × 10–20 days
- Cycle: 4–6 weeks, 2×/year
Dosing Table — Glow Stack
Route: Subcutaneous (SC) — three separate syringes | Frequency: See per peptide
| Week | Dose | Units (per injection) |
|---|---|---|
| 1–2 | GHK-Cu 1mg morning / BPC 250mcg ×2 / Epi 5mg evening | 5 Units (0.05 mL) |
| 3–4 | GHK-Cu 2mg morning / BPC 500mcg ×2 / Epi 5mg evening | 10 Units (0.10 mL) |
| 5–6 | GHK-Cu 2mg morning / BPC 500mcg ×1 / — | 10 Units (0.10 mL) |
GHK-Cu: morning. BPC-157: 2×/day loading, then 1×/day. Epithalon: evening before sleep × 10–20 days (not for the entire cycle). The compounds are handled separately.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
GHK-Cu 50mg (50 mg)
BPC-157 5mg (5 mg)
Epithalon 10mg (10 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- GHK-Cu 50mg: 2.5 mL BAC water → 20 mg/mL.
- BPC-157 5mg: 2 mL BAC water → 2.5 mg/mL.
- Epithalon 10mg: 2 mL BAC water → 5 mg/mL.
- Gently swirl. Use separate syringes.
Protocol Overview
- Goal: Multi-level tissue regeneration via 3 distinct mechanisms.
- Trending 2026 stack in literature (PeptideRundown Feb 2026, BioTech Peptides Mar 2026).
- Status: Purely research-grade — no official clinical trials exist.
Dosing Protocol
- GHK-Cu: 1mg wks 1–2 → 2mg wks 3+, daily morning.
- BPC-157: 250mcg×2 loading wks 1–2 → 500mcg×2 wks 3–4 → 500mcg×1 maintenance.
- Epithalon: 5mg evening × 10–20 days (first 2–3 weeks of cycle).
- Cycle: 4–6 weeks, 2×/year.
- Break between cycles: Stop 6 months between cycles. Epithalon is recommended only 2×/year.
Washout & Cycle Restart
When can I restart?
Stop 6 months between cycles. Epithalon is recommended only 2×/year.
Minimum wait period: 24 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C, use within 4 weeks.
- GHK-Cu may change color (blue-green) — normal.
Important Notes
- Avoid administering Epithalon for more than 20 days per cycle.
- Monitoring: serum free copper (GHK-Cu).
- This protocol is for educational purposes only.
Potential Benefits & Side Effects
Potential Benefits:
- Collagen & elastin synthesis (skin rejuvenation).
- Angiogenesis and improved tissue perfusion.
- Telomere elongation (biological age).
- Antioxidant and anti-inflammatory effects.
- Accelerated wound healing.
Potential Side Effects:
- GHK-Cu: transient injection site discoloration.
- BPC-157: rare mild nausea or fatigue.
- Epithalon: rare local redness.
- No serious adverse events reported.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Telomerase & oncogenesis — conflicting data
Epithalon activates telomerase (hTERT). While it appeared anti-cancer in animal models, telomerase activation is considered a hallmark of cancer. No long-term human studies exist.
📄 Bull Exp Biol Med 2003; Khavinson VKTheoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Angiogenesis & tissue remodeling
GHK-Cu promotes angiogenesis, tissue regeneration, and increases collagen/elastin. Theoretical concern for enhancing existing tumors, though no clinical signal exists.
📄 Life Sci 2012References
- PeptideRundown — Glow Stack (2026) — Skin rejuvenation stack: GHK-Cu + BPC-157 + Epithalon — mechanisms and evidence (February 2026).
View Source - BioTech Peptides — Glow Blend Mechanistic Insights (2026) — GHK-Cu + TB-500 + BPC-157 blend regenerative signaling networks (March 2026).
View Source - Quality in Sport Review (2026) — BPC-157 and GHK-Cu in wound healing and tissue repair — clinical efficacy review.
View Source - GHK-Cu — Pickart 2018 — GHK-Cu: a regenerative peptide. Int J Mol Sci.
View Source - Epithalon — Khavinson 2003 — Epithalon activates telomerase in human somatic cells. Bull Exp Biol Med.
View Source
Recommended Supplements
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Anti-ageing / Telomerase
Phase II in Russia (Khavinson)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →